These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 39050978)

  • 1. Real-World Treatment Patterns and Outcomes of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma Treated in US Oncology Practices.
    Ge W; Wu N; Chen CI; Inocencio TJ; LaFontaine PR; Seebach F; Fury M; Harnett J; Ruiz ES
    Cancer Manag Res; 2024; 16():841-854. PubMed ID: 39050978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Experience With Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma.
    Strum S; Climans S; Purcell V; Black M; Winquist E; Ernst S
    J Cutan Med Surg; 2024; 28(5):453-457. PubMed ID: 39056376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world evidence study on the early use of cemiplimab in the UK: REACT-CEMI (Real World evidence of advanced CSCC treatment with cemiplimab).
    Challapalli A; Stewart G; Shaw H; Davies PJ; Lopez-Baez JC; Ottley EC; Kelly S
    Front Immunol; 2024; 15():1408667. PubMed ID: 39072317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advanced cutaneous squamous cell carcinoma: Impact of age on the safety and efficacy of cemiplimab and the prognostic significance of blood biomarkers.
    Ksienski D; Truong PT; Bone JN; Egli S; Clarkson M; Patterson T; Lesperance M; Lakkunarajah S
    J Geriatr Oncol; 2024 Jun; 15(5):101789. PubMed ID: 38710153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma.
    Baggi A; Quaglino P; Rubatto M; Depenni R; Guida M; Ascierto PA; Trojaniello C; Queirolo P; Saponara M; Peris K; Spagnolo F; Bianchi L; De Galitiis F; Potenza MC; Proietti I; Marconcini R; Botticelli A; Barbieri V; Licitra L; Alfieri S; Ficorella C; Cortellini A; Fargnoli MC; Troiani T; Tondulli L; Bossi P
    Eur J Cancer; 2021 Nov; 157():250-258. PubMed ID: 34536948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cemiplimab in an Elderly Frail Population of Patients With Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Center Real-Life Experience From Italy.
    Strippoli S; Fanizzi A; Quaresmini D; Nardone A; Armenio A; Figliuolo F; Filotico R; Fucci L; Mele F; Traversa M; De Luca F; Montagna ES; Ruggieri E; Ferraiuolo S; Macina F; Tommasi S; Sciacovelli AM; De Risi I; Albano A; Massafra R; Guida M
    Front Oncol; 2021; 11():686308. PubMed ID: 34820323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes among unresectable, locally advanced, and metastatic cutaneous squamous cell carcinoma patients treated with systemic therapy.
    Cowey CL; Robert NJ; Espirito JL; Davies K; Frytak J; Lowy I; Fury MG
    Cancer Med; 2020 Oct; 9(20):7381-7387. PubMed ID: 32578965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Experience with Cemiplimab Treatment for Advanced Cutaneous Squamous Cell Carcinoma-A Retrospective Single-Center Study.
    Kuzmanovszki D; Kiss N; Tóth B; Tóth V; Szakonyi J; Lőrincz K; Hársing J; Kuroli E; Imrédi E; Kerner T; Patyánik M; Wikonkál NM; Szabó Á; Brodszky V; Rencz F; Holló P
    J Clin Med; 2023 Sep; 12(18):. PubMed ID: 37762907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoint inhibitor therapy for advanced cutaneous squamous cell carcinoma in Australia: a retrospective real world cohort study.
    McLean LS; Lim AM; Bressel M; Lee J; Ladwa R; Guminski AD; Hughes B; Bowyer S; Briscoe K; Harris S; Kukard C; Zielinski R; Alamgeer M; Carlino M; Mo J; Park JJ; Khattak MA; Day F; Rischin D
    Med J Aust; 2024 Feb; 220(2):80-90. PubMed ID: 38212673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to First-Line Treatment with Immune-Checkpoint Inhibitors in Patients with Advanced Cutaneous Squamous Cell Carcinoma: A Multicenter, Retrospective Analysis from the German ADOReg Registry.
    Haist M; Stege H; Lang BM; Tsochataridou A; Salzmann M; Mohr P; Schadendorf D; Ugurel S; Placke JM; Weichenthal M; Gutzmer R; Leiter U; Kaatz M; Haferkamp S; Berking C; Heppt M; Tschechne B; Schummer P; Gebhardt C; Grabbe S; Loquai C
    Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cemiplimab for advanced cutaneous squamous cell carcinoma in kidney transplant recipients.
    Van Meerhaeghe T; Baurain JF; Bechter O; Orte Cano C; Del Marmol V; Devresse A; Doubel P; Hanssens M; Hellemans R; Lienard D; Rutten A; Sprangers B; Le Moine A; Aspeslagh S
    Front Nephrol; 2022; 2():1041819. PubMed ID: 37675002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of cemiplimab vs pembrolizumab for treatment of advanced cutaneous squamous cell carcinoma.
    Paul E; Konidaris G; Cope S; Chen CI; Keeping S; Xu Y; Atsou K; Ayers D; Guyot P; Sasane M; Mojebi A; Kuznik A
    J Manag Care Spec Pharm; 2021 Nov; 27(11):1513-1525. PubMed ID: 34351214
    [No Abstract]   [Full Text] [Related]  

  • 13. Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma: Real-World Experience in a Monographic Oncology Center.
    Ríos-Viñuela E; Álvarez P; Lavernia J; Serra-Guillén C; Requena C; Bernia E; Diago A; Llombart B; Sanmartín O
    Actas Dermosifiliogr; 2022 Jun; 113(6):T610-T615. PubMed ID: 35525283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma: Real-World Experience in a Monographic Oncology Center.
    Ríos-Viñuela E; Álvarez P; Lavernia J; Serra-Guillén C; Requena C; Bernia E; Diago A; Llombart B; Sanmartín O
    Actas Dermosifiliogr; 2022 Jun; 113(6):610-615. PubMed ID: 35431057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis.
    Rischin D; Khushalani NI; Schmults CD; Guminski A; Chang ALS; Lewis KD; Lim AM; Hernandez-Aya L; Hughes BGM; Schadendorf D; Hauschild A; Thai AA; Stankevich E; Booth J; Yoo SY; Li S; Chen Z; Okoye E; Chen CI; Mastey V; Sasane M; Lowy I; Fury MG; Migden MR
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34413166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Cemiplimab as Adjuvant or Neoadjuvant Therapy in the Treatment of Cutaneous Squamous Cell Carcinoma.
    Hiller A; Oxford M; Kulkarni P; Fornadley J; Lo A; Sivik J; Drabick J; Vakharia K
    Ann Plast Surg; 2024 Apr; 92(4S Suppl 2):S129-S131. PubMed ID: 38556660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cemiplimab for Locally Advanced and Metastatic Cutaneous Squamous-Cell Carcinomas: Real-Life Experience from the French CAREPI Study Group.
    Hober C; Fredeau L; Pham-Ledard A; Boubaya M; Herms F; Celerier P; Aubin F; Beneton N; Dinulescu M; Jannic A; Meyer N; Duval-Modeste AB; Cesaire L; Neidhardt ÈM; Archier É; Dréno B; Lesage C; Berthin C; Kramkimel N; Grange F; de Quatrebarbes J; Stoebner PE; Poulalhon N; Arnault JP; Abed S; Bonniaud B; Darras S; Heidelberger V; Devaux S; Moncourier M; Misery L; Mansard S; Etienne M; Brunet-Possenti F; Jacobzone C; Lesbazeilles R; Skowron F; Sanchez J; Catala S; Samimi M; Tazi Y; Spaeth D; Gaudy-Marqueste C; Collard O; Triller R; Pracht M; Dumas M; Peuvrel L; Combe P; Lauche O; Guillet P; Reguerre Y; Kupfer-Bessaguet I; Solub D; Schoeffler A; Bedane C; Quéreux G; Dalac S; Mortier L; Maubec È
    Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6.
    Hughes BGM; Guminski A; Bowyer S; Migden MR; Schmults CD; Khushalani NI; Chang ALS; Grob JJ; Lewis KD; Ansstas G; Day F; Ladwa R; Stein BN; Muñoz Couselo E; Meier F; Hauschild A; Schadendorf D; Basset-Seguin N; Modi B; Dalac-Rat S; Dunn LA; Flatz L; Mortier L; Guégan S; Heinzerling LM; Mehnert JM; Trabelsi S; Soria-Rivas A; Stratigos AJ; Ulrich C; Wong DJ; Beylot-Barry M; Bossi P; Bugés Sánchez C; Chandra S; Robert C; Russell JS; Silk AW; Booth J; Yoo SY; Seebach F; Lowy I; Fury MG; Rischin D
    J Am Acad Dermatol; 2025 Jan; 92(1):68-77. PubMed ID: 39245360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-Life Study of the Benefit of Concomitant Radiotherapy with Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma (cSCC): A Retrospective Cohort Study.
    Bailly-Caillé B; Kottler D; Morello R; Lecornu M; Kao W; Meyer E; Dompmartin A; L'Orphelin JM
    Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune Checkpoint Inhibitors in Advanced Cutaneous Squamous Cell Carcinoma: Real-World Experience from a Canadian Comprehensive Cancer Centre.
    Koch Hein EC; Vilbert M; Hirsch I; Fernando Ribeiro M; Muniz TP; Fournier C; Abdulalem K; Saldanha EF; Martinez E; Spreafico A; Hogg DH; Butler MO; Saibil SD
    Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.